Cargando…

Prevalence of clinically actionable disease variants in exceptionally long-lived families

BACKGROUND: Phenotypic expression of pathogenic variants in individuals with no family history of inherited disorders remains unclear. METHODS: We evaluated the prevalence of pathogenic variants in 25 genes associated with Mendelian-inherited disorders in 3015 participants from 485 families in the L...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlson, Paige, Wojczynski, Mary K., Druley, Todd, Lee, Joseph H., Zmuda, Joseph M., Thyagarajan, Bharat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146901/
https://www.ncbi.nlm.nih.gov/pubmed/32272925
http://dx.doi.org/10.1186/s12920-020-0710-5
_version_ 1783520308625408000
author Carlson, Paige
Wojczynski, Mary K.
Druley, Todd
Lee, Joseph H.
Zmuda, Joseph M.
Thyagarajan, Bharat
author_facet Carlson, Paige
Wojczynski, Mary K.
Druley, Todd
Lee, Joseph H.
Zmuda, Joseph M.
Thyagarajan, Bharat
author_sort Carlson, Paige
collection PubMed
description BACKGROUND: Phenotypic expression of pathogenic variants in individuals with no family history of inherited disorders remains unclear. METHODS: We evaluated the prevalence of pathogenic variants in 25 genes associated with Mendelian-inherited disorders in 3015 participants from 485 families in the Long Life Family Study (LLFS). Boot-strapping and Fisher’s exact test were used to determine whether allele frequencies in LLFS were significantly different from the allele frequencies reported in publicly available genomic databases. RESULTS: The proportions of pathogenic autosomal dominant mutation carriers in BRCA1 and SDHC in LLFS study participants were similar to those reported in publicly available genomic databases (0.03% vs. 0.0008%, p = 1 for BRCA1, and 0.08% vs. 0.003%, p = 0.05 for SDHC). The frequency of carriers of pathogenic autosomal recessive variants in CPT2, ACADM, SUMF1, WRN, ATM, and ACADVL were also similar in LLFS as compared to those reported in genomic databases. The lack of clinical disease among LLFS participants with well-established pathogenic variants in BRCA1 and SDHC suggests that penetrance of pathogenic variants may be different in long lived families. CONCLUSION: Further research is needed to better understand the penetrance of pathogenic variants before expanding large scale genomic testing to asymptomatic individuals.
format Online
Article
Text
id pubmed-7146901
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71469012020-04-18 Prevalence of clinically actionable disease variants in exceptionally long-lived families Carlson, Paige Wojczynski, Mary K. Druley, Todd Lee, Joseph H. Zmuda, Joseph M. Thyagarajan, Bharat BMC Med Genomics Research Article BACKGROUND: Phenotypic expression of pathogenic variants in individuals with no family history of inherited disorders remains unclear. METHODS: We evaluated the prevalence of pathogenic variants in 25 genes associated with Mendelian-inherited disorders in 3015 participants from 485 families in the Long Life Family Study (LLFS). Boot-strapping and Fisher’s exact test were used to determine whether allele frequencies in LLFS were significantly different from the allele frequencies reported in publicly available genomic databases. RESULTS: The proportions of pathogenic autosomal dominant mutation carriers in BRCA1 and SDHC in LLFS study participants were similar to those reported in publicly available genomic databases (0.03% vs. 0.0008%, p = 1 for BRCA1, and 0.08% vs. 0.003%, p = 0.05 for SDHC). The frequency of carriers of pathogenic autosomal recessive variants in CPT2, ACADM, SUMF1, WRN, ATM, and ACADVL were also similar in LLFS as compared to those reported in genomic databases. The lack of clinical disease among LLFS participants with well-established pathogenic variants in BRCA1 and SDHC suggests that penetrance of pathogenic variants may be different in long lived families. CONCLUSION: Further research is needed to better understand the penetrance of pathogenic variants before expanding large scale genomic testing to asymptomatic individuals. BioMed Central 2020-04-10 /pmc/articles/PMC7146901/ /pubmed/32272925 http://dx.doi.org/10.1186/s12920-020-0710-5 Text en © The Author(s). 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Carlson, Paige
Wojczynski, Mary K.
Druley, Todd
Lee, Joseph H.
Zmuda, Joseph M.
Thyagarajan, Bharat
Prevalence of clinically actionable disease variants in exceptionally long-lived families
title Prevalence of clinically actionable disease variants in exceptionally long-lived families
title_full Prevalence of clinically actionable disease variants in exceptionally long-lived families
title_fullStr Prevalence of clinically actionable disease variants in exceptionally long-lived families
title_full_unstemmed Prevalence of clinically actionable disease variants in exceptionally long-lived families
title_short Prevalence of clinically actionable disease variants in exceptionally long-lived families
title_sort prevalence of clinically actionable disease variants in exceptionally long-lived families
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146901/
https://www.ncbi.nlm.nih.gov/pubmed/32272925
http://dx.doi.org/10.1186/s12920-020-0710-5
work_keys_str_mv AT carlsonpaige prevalenceofclinicallyactionablediseasevariantsinexceptionallylonglivedfamilies
AT wojczynskimaryk prevalenceofclinicallyactionablediseasevariantsinexceptionallylonglivedfamilies
AT druleytodd prevalenceofclinicallyactionablediseasevariantsinexceptionallylonglivedfamilies
AT leejosephh prevalenceofclinicallyactionablediseasevariantsinexceptionallylonglivedfamilies
AT zmudajosephm prevalenceofclinicallyactionablediseasevariantsinexceptionallylonglivedfamilies
AT thyagarajanbharat prevalenceofclinicallyactionablediseasevariantsinexceptionallylonglivedfamilies